Welcome to our dedicated page for Ardelyx news (Ticker: $ARDX), a resource for investors and traders seeking the latest updates and insights on Ardelyx stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ardelyx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ardelyx's position in the market.
Ardelyx, Inc. (Nasdaq: ARDX) will present additional data supporting IBSRELA® (tenapanor) for adults with irritable bowel syndrome with constipation at the 2024 Digestive Disease Week Conference. IBSRELA is approved by the FDA to treat IBS-C in adults. The presentation will include posthoc analysis from Phase 3 studies and a Product Theater discussing clinical considerations for managing IBS-C.
Ardelyx, Inc. (Nasdaq: ARDX) reported $45.6 million in Q1 product-related revenue, with $28.4 million from IBSRELA and $15.2 million from XPHOZAH. The company ended Q1 with around $203 million in cash and investments. Ardelyx saw significant growth in net product sales revenue for both IBSRELA and XPHOZAH, with plans to expand market position. The company appointed Mike Kelliher as EVP, Corporate Development and Strategy. Total revenue for Q1 2024 was $46.0 million, up from $11.4 million in Q1 2023. Net loss for Q1 2024 was $26.5 million.
Ardelyx, Inc. will present additional data on XPHOZAH® (tenapanor) at the NKF 2024 Spring Clinical Meetings. XPHOZAH, a phosphate absorption inhibitor, is approved for CKD patients on dialysis. The drug offers a unique mechanism of action and will be discussed in various presentations during the event.
